ENBREL(R) FIRST THERAPY SUBMITTED TO FDA SHOWING INHIBITION OF BONE AND JOINT DAMAGE IN PSORIATIC ARTHRITIS PATIENTS Read more about ENBREL(R) FIRST THERAPY SUBMITTED TO FDA SHOWING INHIBITION OF BONE AND JOINT DAMAGE IN PSORIATIC ARTHRITIS PATIENTS
AMGEN ANNOUNCES POSITIVE STUDY RESULTS OF KINERET(R) IN RHEUMATOID ARTHRITIS DISEASE PROGRESSION AND IN THE TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS Read more about AMGEN ANNOUNCES POSITIVE STUDY RESULTS OF KINERET(R) IN RHEUMATOID ARTHRITIS DISEASE PROGRESSION AND IN THE TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
Enbrel(R) Is First Therapy Shown To Inhibit Bone And Joint Damage In Psoriatic Arthritis Patients Read more about Enbrel(R) Is First Therapy Shown To Inhibit Bone And Joint Damage In Psoriatic Arthritis Patients
Enbrel(R) Only TNF Receptor With Five Years Sustained Data In Treatment Of Rheumatoid Arthritis Read more about Enbrel(R) Only TNF Receptor With Five Years Sustained Data In Treatment Of Rheumatoid Arthritis
New Data On Aranesp(R) Dosed Every Other Week In Anemic Chronic Kidney Disease Patients Presented At 35th Annual Meeting Of The American Society Of Nephrology Read more about New Data On Aranesp(R) Dosed Every Other Week In Anemic Chronic Kidney Disease Patients Presented At 35th Annual Meeting Of The American Society Of Nephrology
Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in The Lancet Read more about Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in The Lancet
Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology Read more about Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology
Amgen's Fourth Quarter 2007 Adjusted Earnings Per Share (EPS) Increased 11 Percent to $1.00; Full Year 2007 Adjusted EPS Increased 10 Percent to $4.29 Read more about Amgen's Fourth Quarter 2007 Adjusted Earnings Per Share (EPS) Increased 11 Percent to $1.00; Full Year 2007 Adjusted EPS Increased 10 Percent to $4.29
Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy Read more about Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R)) Read more about Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
